This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CD70 (CD27L)	<p>Studies in mice and in cell culture suggest that CD70-targeted T cell immunotherapy could help treat CD70⁺ cancers. In cell culture, CD70-specific T cells killed CD70⁺ human cancer cells but not CD70⁻ cancer cells. In a mouse model of CD70⁺ human lymphomas, adoptive transfer of CD70-specific T cells decreased tumor burden and increased survival compared with nontransduced T cells. Next steps include generating a clinical-grade retroviral vector that encodes a CD70-specific chimeric antigen receptor and testing it in a Phase I trial.</p> <p>SGN-75, an auristatin-based humanized anti-CD70 antibody-drug conjugate from Seattle Genetics Inc., is in Phase I testing for multiple cancers.</p> <p>Bristol-Myers Squibb Co.'s MDX-1203, an antibody against CD70, is in Phase I testing for renal cancer. The pharma is also developing MDX-1411, a cytotoxic prodrug chemically linked with a human anti-CD70 antibody that is in Phase I testing for cancer.</p> <p>SciBX 4(9); doi:10.1038/scibx.2011.250 Published online March 3, 2011</p>	Provisional patent filed; unavailable for licensing	<p>Shaffer, D.R. <i>et al. Blood</i>; published online Feb. 8, 2011; doi:10.1182/blood-2010-04-278218</p> <p>Contact: Stephen Gottschalk, Baylor College of Medicine, Houston, Texas e-mail: smg@bcm.edu</p>